SEC Form 4 · accession 0001209191-17-058479
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Chodakewitz
Officer — EVP GMDA, CMO
Period of report
Oct 31, 2017
Accepted (ET)
Oct 31, 2017 · 6:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Oct 31, 2017 | S | 1,400 | $142.38 | D | 113,024 | D | |
| Common StockF3,F4 | Oct 31, 2017 | S | 4,100 | $143.46 | D | 108,924 | D | |
| Common StockF3,F5 | Oct 31, 2017 | S | 25,784 | $144.46 | D | 83,140 | D | |
| Common StockF3,F6 | Oct 31, 2017 | S | 19,016 | $145.26 | D | 64,124 | D | |
| Common StockF3,F7 | Oct 31, 2017 | S | 4,700 | $146.52 | D | 59,424 | D | |
| Common StockF3,F8 | Oct 31, 2017 | S | 3,400 | $147.75 | D | 56,024 | D | |
| Common StockF3,F9 | Oct 31, 2017 | S | 1,400 | $148.40 | D | 54,624 | D | |
| Common Stock | Oct 31, 2017 | S | 200 | $149.34 | D | 54,424 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $142.38 (range $141.83 to $142.81).
- F3Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $143.46 (range $142.87 to $143.85).
- F5Open market sales reported on this line occurred at a weighted average price of $144.46 (range $143.90 to $144.89).
- F6Open market sales reported on this line occurred at a weighted average price of $145.26 (range $144.91 to $145.87).
- F7Open market sales reported on this line occurred at a weighted average price of $146.52 (range $146.16 to $147.14).
- F8Open market sales reported on this line occurred at a weighted average price of $147.75 (range $147.18 to $148.15).
- F9Open market sales reported on this line occurred at a weighted average price of $148.40 (range $148.19 to $148.70).